GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OSE Immunotherapeutics SA (XPAR:OSE) » Definitions » EV-to-FCF

OSE Immunotherapeutics (XPAR:OSE) EV-to-FCF : -9.31 (As of May. 15, 2024)


View and export this data going back to 2015. Start your Free Trial

What is OSE Immunotherapeutics EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, OSE Immunotherapeutics's Enterprise Value is €183.97 Mil. OSE Immunotherapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was €-19.76 Mil. Therefore, OSE Immunotherapeutics's EV-to-FCF for today is -9.31.

The historical rank and industry rank for OSE Immunotherapeutics's EV-to-FCF or its related term are showing as below:

XPAR:OSE' s EV-to-FCF Range Over the Past 10 Years
Min: -18.3   Med: -5.08   Max: 129.4
Current: -8.75

During the past 12 years, the highest EV-to-FCF of OSE Immunotherapeutics was 129.40. The lowest was -18.30. And the median was -5.08.

XPAR:OSE's EV-to-FCF is ranked worse than
100% of 378 companies
in the Biotechnology industry
Industry Median: 7.545 vs XPAR:OSE: -8.75

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-15), OSE Immunotherapeutics's stock price is €7.22. OSE Immunotherapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €-1.180. Therefore, OSE Immunotherapeutics's PE Ratio for today is At Loss.


OSE Immunotherapeutics EV-to-FCF Historical Data

The historical data trend for OSE Immunotherapeutics's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OSE Immunotherapeutics EV-to-FCF Chart

OSE Immunotherapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.66 -6.04 -18.64 -7.69 -5.98

OSE Immunotherapeutics Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -18.64 - -7.69 - -5.98

Competitive Comparison of OSE Immunotherapeutics's EV-to-FCF

For the Biotechnology subindustry, OSE Immunotherapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OSE Immunotherapeutics's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OSE Immunotherapeutics's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where OSE Immunotherapeutics's EV-to-FCF falls into.



OSE Immunotherapeutics EV-to-FCF Calculation

OSE Immunotherapeutics's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=183.970/-19.764
=-9.31

OSE Immunotherapeutics's current Enterprise Value is €183.97 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. OSE Immunotherapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was €-19.76 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


OSE Immunotherapeutics  (XPAR:OSE) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

OSE Immunotherapeutics's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=7.22/-1.180
=At Loss

OSE Immunotherapeutics's share price for today is €7.22.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. OSE Immunotherapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €-1.180.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


OSE Immunotherapeutics EV-to-FCF Related Terms

Thank you for viewing the detailed overview of OSE Immunotherapeutics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


OSE Immunotherapeutics (XPAR:OSE) Business Description

Traded in Other Exchanges
Address
22, Boulevard Benoni Goullin, Nantes, FRA, 44200
OSE Immunotherapeutics SA is a France-based biotechnology company focused on the development of immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases. The product portfolio of the company comprises Tedopi, OSE-172, OSE-703, FR104 and OSE-127.

OSE Immunotherapeutics (XPAR:OSE) Headlines

No Headlines